drugset / Trial / NCT02531932
Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of carboplatin compared to the combination of carboplatin and everolimus for the treatment of advanced triple-negative breast cancer (TNBC). Study close to accrual
Timeline
- Start
- 2015-12-16
- Primary completion
- 2024-09-30
- Completion
- 2024-10-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 4 unknown | Intravenous |
| Subject | Everolimus | Small molecule | 5 mg | Oral |